Aurora Cannabis sets Q1 2027 earnings call

Aurora Cannabis Inc. is scheduling an investor conference call to discuss its financial results for the first quarter 2027.

Rhea-AI Filing Summary

Aurora Cannabis Inc. is scheduling an investor conference call to discuss its financial results for the first quarter 2027. The company plans to release these results before market open on August 5, 2026, then hold a webcast at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time).

Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call and a question-and-answer period. Aurora highlights its global, medical-first cannabis strategy and includes detailed cautionary language on forward-looking statements, directing readers to risk factors in its June 11, 2026 annual information form.

Key Figures

Earnings call date: August 5, 2026 Earnings call time (Eastern): 8:00 a.m. Eastern Time Earnings call time (Mountain): 6:00 a.m. Mountain Time +1 more

4 metrics

Earnings call date August 5, 2026 Scheduled date for first quarter 2027 investor conference call

Earnings call time (Eastern) 8:00 a.m. Eastern Time Start time of call to discuss first quarter 2027 results

Earnings call time (Mountain) 6:00 a.m. Mountain Time Mountain Time equivalent for the investor call

Fiscal period First quarter 2027 Financial period to be covered on the August 5, 2026 call

Key Terms

forward-looking statements, annual information form, medical cannabis, GMP-certified

4 terms

forward-looking statements regulatory

"This news release includes statements containing certain "forward-looking information""

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

annual information form regulatory

"factors set out under the heading "Risk Factors" in the Company's annual information form"

A company's annual information form is a comprehensive regulatory filing that lays out its business description, key assets, risks, legal matters and other background details shareholders need to understand the company’s operations. Think of it as a detailed owner’s manual or dossier that supplements financial statements, helping investors do deeper homework on how the business works and what could affect its future performance.

medical cannabis medical

"Aurora is a global leader in medical cannabis, dedicated to improving lives"

Medical cannabis is the use of cannabis plant extracts or compounds such as THC and CBD as prescribed or recommended to treat symptoms or medical conditions. Think of it as a plant-based medicine that can relieve pain, nausea, muscle spasms or other symptoms where conventional drugs may not work; for investors it matters because legal status, clinical evidence, supply rules and insurance coverage determine market size, licensing value and revenue potential.

GMP-certified medical

"With world-class GMP-certified manufacturing facilities in Canada and Germany"

GMP-certified means a manufacturer has been inspected and approved for following Good Manufacturing Practice rules that ensure products are made consistently, safely, and meet quality standards. Think of it like a professional kitchen that follows strict recipes, cleanliness rules and checks so meals are safe every time. For investors, GMP certification lowers regulatory and product-risk, supports market access and brand trust, and can reduce the chance of costly recalls or production shutdowns.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aurora Cannabis (ACB) report its first quarter 2027 results?

Aurora Cannabis plans to release first quarter 2027 financial results before market open on August 5, 2026. An investor conference call and webcast will follow that morning to review the numbers and answer questions.

What are the date and time of Aurora Cannabis (ACB) Q1 2027 investor call?

The Q1 2027 investor conference call is scheduled for Wednesday, August 5, 2026 at 8:00 a.m. Eastern Time / 6:00 a.m. Mountain Time. Management will discuss the quarter’s financial results and take questions.

Who will host Aurora Cannabis (ACB) first quarter 2027 earnings call?

The call will be hosted by Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer. They will present Aurora’s first quarter 2027 results and lead a question-and-answer session with investors and analysts.

How can investors access Aurora Cannabis (ACB) Q1 2027 results webcast?

Investors can access the webcast via a weblink provided in the announcement and posted under “Events” in the “Investor Info” section of Aurora’s website at https://www.auroramj.com/investors/ for live audio and presentation materials.

What risks are highlighted in Aurora Cannabis (ACB) forward-looking statements?

Aurora notes that forward-looking statements involve risks related to tariffs, financing, competition, integration of acquisitions, consumer demand, regulatory changes, and public health crises, referring readers to the “Risk Factors” section of its June 11, 2026 annual information form.

What markets and brands does Aurora Cannabis (ACB) focus on?

Aurora focuses on medical-first, high-margin cannabis opportunities across Canada, Europe, Australia, and New Zealand. Its brands include Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's, and Whistler Medical Marijuana Co.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/22/2026 - 07:13 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File No. 001-38691

AURORA CANNABIS INC. (Translation of registrant's name into English)

2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  ☐ Form 40-F  ☒

SUBMITTED HEREWITH

Exhibits		Description
99.1		News release dated July 22, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Miguel Martin

Miguel Martin
Chief Executive Officer

Date: July 22, 2026

Exhibit 99.1 

 

Aurora Cannabis to Host First Quarter 2027 Investor Conference Call

NASDAQ | TSX: ACB

EDMONTON, AB, July 22, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that will host an investor conference call on Wednesday, August 5, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its financial results for the first quarter 2027. The Company will report its financial results prior to market open that same morning.

 

Q1 FY27 Earnings

Investor Conference Call Details

DATE:	Wednesday, August 5, 2026
TIME:	8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time
WEBCAST:	Click Here

Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".

About Aurora Cannabis

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora^®, MedReleaf^®, Pedanios^®, IndiMed™, San Raf^®, Tasty's^® and Whistler Medical Marijuana Co.^® With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's fiscal 2027 first quarter financial statements and the conference call to discuss the results.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 11, 2026 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-first-quarter-2027-investor-conference-call-302832540.html

SOURCE Aurora Cannabis Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2026/22/c1362.html

%CIK: 0001683541

For further information: For Media: Michelle Lefler, VP, Communications & PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com

CO: Aurora Cannabis Inc.

CNW 16:05e 22-JUL-26

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 NEWS RELEASE DATED JULY 22, 2026 10.3 KB